Deciphera 
Welcome,         Profile    Billing    Logout  
 7 Products   8 Diseases  7 Products   13 Trials   968 News 
22 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rebastinib (DCC-2036) / Ono Pharma
NCT03717415: A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Checkmark Data from dose escalation phase of a trial in combination with carboplatin for advanced or metastatic solid tumors at ESMO 2020
Sep 2020 - Oct 2020: Data from dose escalation phase of a trial in combination with carboplatin for advanced or metastatic solid tumors at ESMO 2020
Checkmark From trial in combination with carboplatin for metastatic solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with carboplatin for metastatic solid tumors at ESMO 2020
Terminated
1/2
70
US
Rebastinib, DCC-2036, Carboplatin
Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
05/22
11/22
DCC-2036-01-003, NCT03601897: A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Checkmark From P2 part for advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From P2 part for advanced solid tumors at ESMO 2020
Checkmark Data in combination with paclitaxel for advanced ovarian cancer
Sep 2020 - Sep 2020: Data in combination with paclitaxel for advanced ovarian cancer
Checkmark Data from Part 2 of a trial in combination with paclitaxel for advanced or metastatic platinum-resistant ovarian cancer at ESMO 2020
More
Terminated
1/2
177
US
Rebastinib, DCC-2036, Paclitaxel
Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
05/22
05/22
Qinlock (ripretinib) / Ono Pharma
INTRIGUE, NCT03673501 / 2018-001803-35: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruiting
3
453
Europe, Canada, US, RoW
Ripretinib, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
09/21
12/25
INSIGHT, NCT05734105: A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Recruiting
3
54
Europe, Canada, US, RoW
Ripretinib, QINLOCK, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals, LLC
GIST
02/26
12/27
NCT05957367: A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting
1/2
94
US
Inlexisertib, DCC-3116, Ripretinib, QINLOCK, DCC-2618
Deciphera Pharmaceuticals, LLC, Pfizer
GIST
03/27
03/29
NCT04530981: A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Completed
1
13
US
Ripretinib, QINLOCK, Repaglinide
Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
11/23
07/24
NCT05132738: Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

Recruiting
N/A
20
RoW
Ripretinib treatment
RenJi Hospital
Gastrointestinal Stromal Tumors
11/23
11/23
NCT06507683: Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

Recruiting
N/A
32
RoW
simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
First Affiliated Hospital of Chongqing Medical University, Peking University Cancer Hospital & Institute
Gastrointestinal Stromal Tumors
07/27
07/27
NCT06431451: The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs

Recruiting
N/A
60
RoW
First Affiliated Hospital, Sun Yat-Sen University
Gastrointestinal Stromal Tumors
12/25
12/25
INTEREST, NCT06619275: Ripretinib (QINLOCK®) According to Current SmPC

Recruiting
N/A
100
Europe
Ripretinib
iOMEDICO AG, Deciphera Pharmaceuticals (Switzerland) AG
GIST - Gastrointestinal Stromal Tumor
09/27
11/27
ChiCTR2500098778: Study on the blood concentration of ripretinib in Chinese patients with gastrointestinal stromal tumors

Not yet recruiting
N/A
100
 
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University
Gastrointestinal Stromal Tumors
 
 
ChiCTR2400082253: A single-centre, non-randomised, single-arm clinical study: evaluating the efficacy and safety of radiotherapy in combination with ripretinib for unresectable advanced GIST

Not yet recruiting
N/A
32
 
Radiotherapy combined with oral ripretinib
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Self-funded
Gastrointestinal Stromal Tumors
 
 
ChiCTR2500101836: A multicenter, randomized, controlled study of ripretinib in combination with sunitinib versus rifitinib plus top-dose therapy in advanced GIST with fourth-line therapy

Not yet recruiting
N/A
60
 
Rapatinib 150 mg combined with Sunitinib 25 mg qd; The patient is taking 150mg bid of Rapatinib
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University), Self-selected project (self-funded)
Gastrointestinal stromal tumors
 
 
NCT05697107: Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

Active, not recruiting
N/A
308
RoW
Ripretinib Oral Tablet
Peking University, First Affiliated Hospital, Sun Yat-Sen University, Wuhan Union Hospital, China, Sun Yat-sen University, Fudan University, Xiangya Hospital of Central South University, Fujian Medical University Union Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Chongqing Medical University, RenJi Hospital
Gastrointestinal Stromal Tumors
08/22
12/23
NCT05354388: Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study

Recruiting
N/A
30
RoW
Resection surgery of gastrointestinal stromal tumor
Sichuan Provincial People's Hospital
Gastrointestinal Stromal Tumor(GIST)
12/23
12/23
Romvimza (vimseltinib) / Ono Pharma
2020-004883-25: This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2 parts: Part 1 is double blinded and Part 2 is open label study

Not yet recruiting
3
120
Europe
vimseltinib, DCC-3014, Capsule
Deciphera Pharmaceuticals, LLC, DECIPHERA PHARMACEUTICALS, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, TGCT is a rare tumor arising from the joints (i.e. synovium of joints, bursae, and tendon sheaths), Diseases [C] - Cancer [C04]
 
 
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
123
Europe, Canada, US, RoW
Vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
NCT06619561: A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Recruiting
2
36
US
Vimseltinib, DCC-3014
Deciphera Pharmaceuticals, LLC
Chronic Graft-Versus-Host Disease (cGVHD)
10/29
10/29
DCC-3014-01-001, NCT03069469: Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Active, not recruiting
1/2
120
Europe, Canada, US, RoW
Vimseltinib, DCC-3014
Deciphera Pharmaceuticals, LLC
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
07/26
08/28
NCT04242238: Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Active, not recruiting
1
32
US
DCC-3014, Avelumab
Memorial Sloan Kettering Cancer Center, ENABLE MEDICINE
Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Dedifferentiated Liposarcoma
01/26
01/26
inlexisertib (DCC-3116) / Ono Pharma
NCT04892017: A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
144
US
Inlexisertib, DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals, LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
DCC-3084 / Ono Pharma
DCC-3084-01-001, NCT06287463: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Recruiting
1/2
140
US
DCC-3084
Deciphera Pharmaceuticals, LLC
Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
08/26
08/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rebastinib (DCC-2036) / Ono Pharma
NCT03717415: A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Checkmark Data from dose escalation phase of a trial in combination with carboplatin for advanced or metastatic solid tumors at ESMO 2020
Sep 2020 - Oct 2020: Data from dose escalation phase of a trial in combination with carboplatin for advanced or metastatic solid tumors at ESMO 2020
Checkmark From trial in combination with carboplatin for metastatic solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with carboplatin for metastatic solid tumors at ESMO 2020
Terminated
1/2
70
US
Rebastinib, DCC-2036, Carboplatin
Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
05/22
11/22
DCC-2036-01-003, NCT03601897: A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Checkmark From P2 part for advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From P2 part for advanced solid tumors at ESMO 2020
Checkmark Data in combination with paclitaxel for advanced ovarian cancer
Sep 2020 - Sep 2020: Data in combination with paclitaxel for advanced ovarian cancer
Checkmark Data from Part 2 of a trial in combination with paclitaxel for advanced or metastatic platinum-resistant ovarian cancer at ESMO 2020
More
Terminated
1/2
177
US
Rebastinib, DCC-2036, Paclitaxel
Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
05/22
05/22
Qinlock (ripretinib) / Ono Pharma
INTRIGUE, NCT03673501 / 2018-001803-35: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruiting
3
453
Europe, Canada, US, RoW
Ripretinib, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
09/21
12/25
INSIGHT, NCT05734105: A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Recruiting
3
54
Europe, Canada, US, RoW
Ripretinib, QINLOCK, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals, LLC
GIST
02/26
12/27
NCT05957367: A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting
1/2
94
US
Inlexisertib, DCC-3116, Ripretinib, QINLOCK, DCC-2618
Deciphera Pharmaceuticals, LLC, Pfizer
GIST
03/27
03/29
NCT04530981: A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Completed
1
13
US
Ripretinib, QINLOCK, Repaglinide
Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
11/23
07/24
NCT05132738: Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

Recruiting
N/A
20
RoW
Ripretinib treatment
RenJi Hospital
Gastrointestinal Stromal Tumors
11/23
11/23
NCT06507683: Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

Recruiting
N/A
32
RoW
simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
First Affiliated Hospital of Chongqing Medical University, Peking University Cancer Hospital & Institute
Gastrointestinal Stromal Tumors
07/27
07/27
NCT06431451: The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs

Recruiting
N/A
60
RoW
First Affiliated Hospital, Sun Yat-Sen University
Gastrointestinal Stromal Tumors
12/25
12/25
INTEREST, NCT06619275: Ripretinib (QINLOCK®) According to Current SmPC

Recruiting
N/A
100
Europe
Ripretinib
iOMEDICO AG, Deciphera Pharmaceuticals (Switzerland) AG
GIST - Gastrointestinal Stromal Tumor
09/27
11/27
ChiCTR2500098778: Study on the blood concentration of ripretinib in Chinese patients with gastrointestinal stromal tumors

Not yet recruiting
N/A
100
 
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University
Gastrointestinal Stromal Tumors
 
 
ChiCTR2400082253: A single-centre, non-randomised, single-arm clinical study: evaluating the efficacy and safety of radiotherapy in combination with ripretinib for unresectable advanced GIST

Not yet recruiting
N/A
32
 
Radiotherapy combined with oral ripretinib
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Self-funded
Gastrointestinal Stromal Tumors
 
 
ChiCTR2500101836: A multicenter, randomized, controlled study of ripretinib in combination with sunitinib versus rifitinib plus top-dose therapy in advanced GIST with fourth-line therapy

Not yet recruiting
N/A
60
 
Rapatinib 150 mg combined with Sunitinib 25 mg qd; The patient is taking 150mg bid of Rapatinib
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University), Self-selected project (self-funded)
Gastrointestinal stromal tumors
 
 
NCT05697107: Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

Active, not recruiting
N/A
308
RoW
Ripretinib Oral Tablet
Peking University, First Affiliated Hospital, Sun Yat-Sen University, Wuhan Union Hospital, China, Sun Yat-sen University, Fudan University, Xiangya Hospital of Central South University, Fujian Medical University Union Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Chongqing Medical University, RenJi Hospital
Gastrointestinal Stromal Tumors
08/22
12/23
NCT05354388: Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study

Recruiting
N/A
30
RoW
Resection surgery of gastrointestinal stromal tumor
Sichuan Provincial People's Hospital
Gastrointestinal Stromal Tumor(GIST)
12/23
12/23
Romvimza (vimseltinib) / Ono Pharma
2020-004883-25: This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2 parts: Part 1 is double blinded and Part 2 is open label study

Not yet recruiting
3
120
Europe
vimseltinib, DCC-3014, Capsule
Deciphera Pharmaceuticals, LLC, DECIPHERA PHARMACEUTICALS, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, TGCT is a rare tumor arising from the joints (i.e. synovium of joints, bursae, and tendon sheaths), Diseases [C] - Cancer [C04]
 
 
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
123
Europe, Canada, US, RoW
Vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
NCT06619561: A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Recruiting
2
36
US
Vimseltinib, DCC-3014
Deciphera Pharmaceuticals, LLC
Chronic Graft-Versus-Host Disease (cGVHD)
10/29
10/29
DCC-3014-01-001, NCT03069469: Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Active, not recruiting
1/2
120
Europe, Canada, US, RoW
Vimseltinib, DCC-3014
Deciphera Pharmaceuticals, LLC
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
07/26
08/28
NCT04242238: Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Active, not recruiting
1
32
US
DCC-3014, Avelumab
Memorial Sloan Kettering Cancer Center, ENABLE MEDICINE
Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Dedifferentiated Liposarcoma
01/26
01/26
inlexisertib (DCC-3116) / Ono Pharma
NCT04892017: A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
144
US
Inlexisertib, DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals, LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
DCC-3084 / Ono Pharma
DCC-3084-01-001, NCT06287463: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Recruiting
1/2
140
US
DCC-3084
Deciphera Pharmaceuticals, LLC
Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
08/26
08/27

Download Options